Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,218
  • Shares Outstanding, K 31,038
  • Annual Sales, $ 57,680 K
  • Annual Income, $ -46,000 K
  • EBIT $ -83 M
  • EBITDA $ -74 M
  • 60-Month Beta 1.38
  • Price/Sales 1.47
  • Price/Cash Flow N/A
  • Price/Book 1.40

Options Overview Details

View History
  • Implied Volatility 216.24% (+99.16%)
  • Historical Volatility 66.10%
  • IV Percentile 65%
  • IV Rank 16.06%
  • IV High 1,000.47% on 11/10/25
  • IV Low 66.25% on 11/20/25
  • Expected Move (DTE 15) 1.07 (34.77%)
  • Put/Call Vol Ratio 1.50
  • Today's Volume 50
  • Volume Avg (30-Day) 349
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 16,117
  • Open Int (30-Day) 16,952
  • Expected Range 2.01 to 4.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.42
  • Number of Estimates 1
  • High Estimate 0.42
  • Low Estimate 0.42
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +261.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.00 +3.33%
on 02/06/26
4.22 -26.54%
on 02/23/26
+0.17 (+5.80%)
since 02/05/26
3-Month
2.78 +11.71%
on 12/08/25
4.53 -31.57%
on 01/09/26
+0.27 (+9.54%)
since 12/05/25
52-Week
1.33 +133.08%
on 04/09/25
4.53 -31.57%
on 01/09/26
+1.54 (+98.72%)
since 03/05/25

Most Recent Stories

More News
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...

FBIO : 3.13 (+0.97%)
FBIOP : 13.90 (-1.77%)
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...

FBIO : 3.13 (+0.97%)
FBIOP : 13.90 (-1.77%)
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE...

FBIO : 3.13 (+0.97%)
ATXI : 0.1771 (-33.74%)
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million...

FBIO : 3.13 (+0.97%)
FBIOP : 13.90 (-1.77%)
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the...

FBIO : 3.13 (+0.97%)
FBIOP : 13.90 (-1.77%)
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on...

FBIO : 3.13 (+0.97%)
DERM : 7.89 (-1.87%)
Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech: Q3 Earnings Snapshot

FBIO : 3.13 (+0.97%)
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights 

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received...

FBIO : 3.13 (+0.97%)
FBIOP : 13.90 (-1.77%)
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold...

FBIO : 3.13 (+0.97%)
DERM : 7.89 (-1.87%)
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

FBIO : 3.13 (+0.97%)
ATXI : 0.1771 (-33.74%)
AXSM : 160.03 (-2.47%)

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

3rd Resistance Point 3.30
2nd Resistance Point 3.25
1st Resistance Point 3.17
Last Price 3.13
1st Support Level 3.04
2nd Support Level 2.99
3rd Support Level 2.91

See More

52-Week High 4.53
Fibonacci 61.8% 3.31
Last Price 3.13
Fibonacci 50% 2.93
Fibonacci 38.2% 2.55
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar